`
`New Copaxone Formulation Could Help Teva Retain Market Share | AIS Health
`
`Home About AIS Contact AIS Customer Service Advertising & Sponsorships
`
`My Account
`
` My Cart
`
` Log In
`
`Search AISHealth.com
`
`Upcoming Webinar Jan 20, 2016
`Oral Oncology Drugs: Health Plan
`Strategies for a Dynamic Market
`
`MarketPlace AIS Blogs ENewsletters
`
`Search
`
`Renewal Center Advertising & Sponsorships
`
`Already a member? Log in
`
`AIS Blogs › Pharmacy Benefit Management › New Copaxone Formulation Could Help Teva Retain Market Share
`
`New Copaxone Formulation Could Help Teva Retain
`Market Share
`
`By Angela Maas February 19, 2014
`
`Like
`
`0
`
`
`With market share eroding for Teva’s multiple sclerosis therapy Copaxone (glatiramer acetate),
`the manufacturer recently launched a new formulation of the drug that could help it retain its
`footing. And a somewhat different approach in pricing for the new version could seal the deal.
`
`Copaxone was approved in 1996 with daily 20 mg/mL dosing. But the new 40 mg/mL version is
`administered three times a week and offers “essentially equivalent efficacy as the 20 mg dosing level,”
`Stephen Cichy, founder and managing director at Monarch Specialty Group, LLC, tells Specialty Pharmacy
`News. However, it also provides “a simpler dosing regimen. Injections three times per week versus daily”
`means “the sole focus of the new formulation is on injection fatigue.”
`
`While the original formulation will remain available, Teva has said it hopes to convert people on that drug to
`the newer formulation. With Copaxone’s patent due to expire in May, the sooner that could happen, the better.
`
`It's quick and easy to sign up for FREE
`access to AISHealth.com!
`
`According to Boris Gorsh, a manager of syndicated research at Zitter Health Insights, the Wholesale
`Acquisition Cost (WAC) for the new Copaxone formulation is $4,641.24 per month — a decrease from the
`$5,060.33 per month Copaxone daily. Pricing the new formulation a little less than the 20 mg version “is an
`interesting strategy as it is cheaper than daily Copaxone, which can be related to the requirement of less
`syringes, but also to encourage payers to allow patients to make the switch prior to a generic version,” he
`says.
`
`Why do I need to register?
`
`About the AIS Bloggers
`Jill Brown
`Executive Editor
`View Jill's Profile
`
`While Teva makes the 20 mg formulation available for a $35 copay, the company is waiving copays
`indefinitely for the 40 mg, which is an additional incentive for people to switch, points out David Lassen, chief
`clinical officer at Prime Therapeutics LLC. For payers, “Since this is a new formulation of an existing drug with
`similar safety and efficacy profiles, pricing will be a determining factor. The dosing advantage will also come
`into consideration.”
`
`What do you think of this Teva strategy? Can you see other drugmakers adopting it?
`
`To request a free sample copy of Angela’s newsletter, Specialty Pharmacy News, send an email to
`goliver@aishealth.com.
`
`Patrick Connole
`Managing Editor, Health
`Plan Week
`View Patrick's Profile
`
`Steve Davis
`Managing Editor, Inside
`Health Insurance
`Exchanges and The AIS
`Report on Blue Cross and
`Blue Shield Plans*
`View Steve's Profile
`
`Francie Fernald
`Managing Editor
`View Francie's Profile
`
`James Gutman
`Managing Editor, Medicare
`Advantage News
`View James's Profile
`
`Angela Maas
`Managing Editor, Specialty
`Pharmacy News, Drug
`Benefit News and AIS E
`Media
`View Angela's Profile
`
`Nina Youngstrom
`
`http://aishealth.com/blog/pharmacy-benefit-management/new-copaxone-formulation-could-help-teva-retain-market-share
`
`1/2
`
`MYLAN PHARMS. INC. EXHIBIT 1122 PAGE 1
`
`
`
`12/31/2015
`0 Comments
`
`AISHealth
`
` Recommend
`
`
`
` Share⤤
`
`Start the discussion…
`
`New Copaxone Formulation Could Help Teva Retain Market Share | AIS Health
`Managing Editor, Report on
` Login
`Medicare Compliance
`View Nina's Profile
`
`1
`Sort by Best
`
`Theresa
`Defino
`Editor,
`Report on
`Patient
`Privacy and Report on Research
`Compliance
`View Theresa's Profile
`
`Lauren Flynn Kelly
`Editor, Drug Benefit News
`View Lauren's Profile
`
`Lauren Clason
`Associate Editor, Report on
`Patient Privacy
`View Lauren's Profile
`
`Rick Biehl
`President & Publisher
`View Rick's Profile
`
`AIS Staff
`View AIS's Profile
`
`Featured Pharmacy Benefit
`Management Products
`Quality Programs in Cancer Care: A
`Case Study of the Aetna Model
`Specialty Pharmacy News
`Drug Benefit News
`Oral Oncology Drugs: Health Plan
`Strategies for a Dynamic Market
`Specialty Pharmacy Trends and
`Strategies: 2015
`Strategies for Making ValueBased
`Rx Deals in a VolumeBased World
`
`Visit the MarketPlace
`
`ALSO ON AISHEALTH
`How Can We Bring Down the High Prices
`of Drugs?
`1 comment • 2 years ago
`Roger — Alternative and herbal
`complimentary medicine including
`acupuncture to reduce the dosage and …
`Iowa CO-OP Is in ‘Hazardous Financial
`Condition’…Are More at Risk?
`2 comments • a year ago
`AvatarShoreman2 — My father had a saying for
`government plans like this, he called them
`Vast new programs built on half vast ideas. …
`
`WHAT'S THIS?
`How Many CO-OPs Will Be Left in 2016?
`1 comment • 4 months ago
`Marlin McKelvy — Of course, this will be
`another largely failed experiment foisted upon
`the American public as we have seen with …
`
`WellCare: Is This the End of the Beginning
`or the Beginning of the End?
`1 comment • 2 years ago
`AvatarBart Smith — And now a few months later,
`look at WellCare's earnings and stock price.
`The "interim" CEO has no health care …
`
`Subscribe
`
`✉
`
`d
`
`Add Disqus to your site Add Disqus Add
`
`Privacy
`
`
`
`Marketplace
`
` About AIS
`
` Contact AIS
`
` Press Releases
`
` Customer Service
`
` Renew Subscription
`
` Advertising & Sponsorships
`
` FAQs
`
` My Cart
`
`Atlantic Information Services, Inc. 1100 17th Street NW, Suite 300, Washington, DC 20036 8005214323
`Copyright © 2015 Atlantic Information Services, Inc. All Rights Reserved.
`
`Sitemap Privacy Policy Back to Top
`
`Follow @AISHealth
`
`http://aishealth.com/blog/pharmacy-benefit-management/new-copaxone-formulation-could-help-teva-retain-market-share
`
`2/2
`
`Be the first to comment.
`
`MYLAN PHARMS. INC. EXHIBIT 1122 PAGE 2